Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zsolt Talloczy

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Autophagy|April 17, 2008
Adaptive autophagy in Alexander disease-affected astrocytesGuomei Tang, Zhenyu Yue, Zsolt Talloczy, et al.
Journal of Neurochemistry|April 4, 2008
Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and diseaseDavid Sulzer, Eugene Mosharov, Zsolt Talloczy, et al.
Frontiers in Immunology|December 16, 2020
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1Jui-Cheng Tseng, James Cheng-Chung Wei, Atul Deodhar, et al.
Rheumatology (Oxford, England)|December 28, 2018
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 studyJürgen Braun, Xenofon Baraliakos, Atul Deodhar, et al.
Circulation|October 18, 2023
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical TrialFrederick Raal, Ronen Durst, Ran Bi, et al.
Rheumatology and Therapy|August 20, 2018
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 StudyAlan J Kivitz, Ulf Wagner, Eva Dokoupilova, et al.
Human Molecular Genetics|February 16, 2008
Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathwaysGuomei Tang, Zhenyu Yue, Zsolt Talloczy, et al.
Rheumatology International|November 13, 2021
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trialsMaxime Dougados, Uta Kiltz, Alan Kivitz, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trialXenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, et al.
RMD Open|October 1, 2019
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension studyXenofon Baraliakos, Juergen Braun, Atul Deodhar, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Autophagy|April 17, 2008
Adaptive autophagy in Alexander disease-affected astrocytesGuomei Tang, Zhenyu Yue, Zsolt Talloczy, et al.
Journal of Neurochemistry|April 4, 2008
Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and diseaseDavid Sulzer, Eugene Mosharov, Zsolt Talloczy, et al.
Frontiers in Immunology|December 16, 2020
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1Jui-Cheng Tseng, James Cheng-Chung Wei, Atul Deodhar, et al.
Rheumatology (Oxford, England)|December 28, 2018
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 studyJürgen Braun, Xenofon Baraliakos, Atul Deodhar, et al.
Circulation|October 18, 2023
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical TrialFrederick Raal, Ronen Durst, Ran Bi, et al.
Rheumatology and Therapy|August 20, 2018
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 StudyAlan J Kivitz, Ulf Wagner, Eva Dokoupilova, et al.
Human Molecular Genetics|February 16, 2008
Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathwaysGuomei Tang, Zhenyu Yue, Zsolt Talloczy, et al.
Rheumatology International|November 13, 2021
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trialsMaxime Dougados, Uta Kiltz, Alan Kivitz, et al.
Clinical and Experimental Rheumatology|May 19, 2017
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trialXenofon Baraliakos, Alan J Kivitz, Atul A Deodhar, et al.
RMD Open|October 1, 2019
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension studyXenofon Baraliakos, Juergen Braun, Atul Deodhar, et al.
Pageof 2